Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-TN-III neoadjuvant sacituzumab govitecan with or without pembrolizumab in low-risk triple-negative early breast cancer
2023-508787-29-00Phase 2Authorised
- Sponsor
- Westdeutsche Studiengruppe
- Start
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing Sacituzumab govitecan with Sacituzumab govitecan + pembrolizumab (2 arms). Primary endpoints: Pathologic complete response and 3-year invasive disease-free survival. Planned start Mar 2024; status: authorised.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2023-508787-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508787-29-00.